Skip to main content
letter
. 2023 Jul 18;13:32. doi: 10.1186/s12348-023-00336-3

Fig. 1.

Fig. 1

Evolution of patient 3 visual acuity and macular edema on infliximab, subcutaneous (SC) tocilizumab and after the switch for intravenous (IV) tocilizumab. D: day, VA: visual acuity